Consolidation in AML: Abundant opinion and much unknown

Weigert, Nir; Rowe, Jacob M.; Lazarus, Hillard M.; Salman, Meira Yisraeli

doi:10.1016/j.blre.2021.100873

Cited by 5 publications

(2 citation statements)

References 103 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cytarabine is a chemotherapy agent that is used for intensive and consolidation therapy [32]. However, due to unpredictable response rate, the dose and duration of cytarabine in consolidation therapy remain controversial [33,34]. The ERS-5 model can identify patients who are t for consolidation therapy with high-dose cytarabine (Fig.…”

Section: Discussionmentioning

confidence: 99%

The ER stress related gene panel guide the prognosis and chemosensitivity in acute myeloid leukemia

Ren,

Peng,

Long

et al. 2024

Preprint

View full text Add to dashboard Cite

Background Acute myeloid leukemia possess high heterogeneity and current European Leukemia Net (ELN) risk stratification system cannot be applicable to all AML patients and needs about 3 weeks testing cycle. The aim of this study was to develop a applicable prognostic tool that may overcome the above shortcomings. Methods We used AML patients collected in clinic and TCGA database to explore the role of ER stress in response to chemotherapy. Patients from the TCGA database were used as the training cohort, and two GEO datasets were used as external validation cohorts. Univariate /multivariate COX and LASSO regression was exemplified to establish the prognostic model. Kaplan-Meier and time-dependent ROC were used to assess and compare the efficiency of the model with ELN stratification and other models. R package "pRRophetic" was utilized to assess drug sensitivity. Results In the training cohort, we selected 5 ER stress-related genes to predict chemosensitivity and establish the ERS-5 prognostic model. The model successfully predicted the overall survival of patients; p < 0.0001, HR = 4.86 (2.79–8.44); AUC = 0.83. The model was verified in validation cohorts and could further stratify the risk of various AML subgroups. It also complemented the ability of ELN to predict the response of patients with AML to main chemotherapeutic drugs. Finally, a “ERS-5” risk score was construced by the nomogram based on the ERS-5 model and age. Conclusions The ERS-5 model allowed more rapid (about 3 hours) and accurate risk stratification and complemented the ability of ELN to assess chemosensitivity.

show abstract

Section: Discussionmentioning

confidence: 99%

The ER stress related gene panel guide the prognosis and chemosensitivity in acute myeloid leukemia

Ren,

Peng,

Long

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Acute myeloid leukemia (AML) is a progressive myeloproliferative malignant tumor, which is mainly characterized by abnormal proliferation of primitive and immature myeloid cells in the bone marrow (BM) and PB (60). It has been shown that there is an abnormally high CD39 expression in Treg cells in patients with AML (35).…”

Section: Acute Myeloid Leukemiamentioning

confidence: 99%

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy

Jiang

Wu²,

Xiao³

et al. 2023

Front. Immunol.

View full text Add to dashboard Cite

Hematological malignancy develops and applies various mechanisms to induce immune escape, in part through an immunosuppressive microenvironment. Adenosine is an immunosuppressive metabolite produced at high levels within the tumor microenvironment (TME). Adenosine signaling through the A2A receptor expressed on immune cells, such as T cells, potently dampens immune responses. Extracellular adenosine generated by ectonucleoside triphosphate diphosphohydrolase-1 (CD39) and ecto-5’-nucleotidase (CD73) molecules is a newly recognized ‘immune checkpoint mediator’ and leads to the identification of immunosuppressive adenosine as an essential regulator in hematological malignancies. In this Review, we provide an overview of the detailed distribution and function of CD39 and CD73 ectoenzymes in the TME and the effects of CD39 and CD73 inhibition on preclinical hematological malignancy data, which provides insights into the potential clinical applications for immunotherapy.

show abstract

Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients

et al. 2023

View full text Add to dashboard Cite

Consolidation in AML: Abundant opinion and much unknown

Cited by 5 publications

References 103 publications

The ER stress related gene panel guide the prognosis and chemosensitivity in acute myeloid leukemia

The ER stress related gene panel guide the prognosis and chemosensitivity in acute myeloid leukemia

The ectonucleotidases CD39 and CD73 on T cells: The new pillar of hematological malignancy

Impact of gemtuzumab ozogamicin consolidation on hematopoietic stem cells (HSCs) mobilization in AML: analysis of 20 patients

Contact Info

Product

Resources

About